<- Go Home
LTR Pharma Limited
LTR Pharma Limited, a biopharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.
Market Cap
AUD 125.8M
Volume
511.6K
Cash and Equivalents
AUD 3.1M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
AUD 49.0K
Profit Margin
100.00%
52 Week High
AUD 2.15
52 Week Low
AUD 0.23
Dividend
N/A
Price / Book Value
32.95
Price / Earnings
-13.93
Price / Tangible Book Value
32.95
Enterprise Value
AUD 122.7M
Enterprise Value / EBITDA
N/A
Operating Income
-AUD 6.9M
Return on Equity
277.45%
Return on Assets
-158.79
Cash and Short Term Investments
AUD 3.1M
Debt
N/A
Equity
AUD 2.9M
Revenue
AUD 49.0K
Unlevered FCF
-AUD 2.8M
Sector
Pharmaceuticals
Category
N/A